Otolog Transplantasyon Sonrası Multipl Miyelom Hastasında Guillain Barré Sendromu: Olgu Sunumu

Yıl 2021, Cilt: 7 Sayı: 3, 479 - 482, 01.09.2021

Ahmet Seyhanlı İsmail Selimoğlu İnci Alacacıoğlu Fatih Demirkan Güner Hayri Özsan

https://doi.org/10.53394/akd.981986

Öz

Guillain-Barre sendromu (GBS), çoklu sinir köklerini ve periferik sinirleri etkileyen bağışıklık aracılı bir periferik nöropatidir. Patogenez tam olarak anlaşılamamıştır ve etiyolojisi belirsizdir. Enfeksiyonlar, maligniteler, aşılama ve kemik iliği nakli suçlanmıştır. Plazmaferez ve intravenöz immünoglobulin tedavi için kullanılabilir. Multipl miyelom, klonal plazma hücrelerinin anormal proliferasyonu ile karakterize malign bir hastalıktır. Kemoterapi ve otolog transplantasyon, multipl miyelom için birincil tedavilerdir. Burada plazmaferez ile düzelen otolog transplantasyon sonrası Guillain-Barre sendromu gelişen multipl miyelom olgusu sunulmuştur.

Anahtar Kelimeler

Guillan Barre sendromu, Multiple myeloma, Periferik otolog kök hücre nakli

Guillain Barré Syndrome in a Multiple Myeloma Patient After the Autologous Transplantation: A Case Report

Öz

Guillain-Barre syndrome (GBS) is an immune-mediated peripheral neuropathy involving multiple nerve roots and peripheral nerves. The pathogenesis remains incompletely understood, and etiology is unclear. Infections, malignancies, vaccination, and bone marrow transplantation have been accused. Plasmapheresis and intravenous immunoglobulin can be used for treatment. Multiple myeloma is a malignant disease characterized by an abnormal proliferation of clonal plasma cells. Chemotherapy and autologous transplantation are primary therapies for multiple myeloma. Herein a case of multiple myeloma developing Guillain-Barre syndrome after autologous transplantation improved by plasmapheresis is presented.

Anahtar Kelimeler

Guillain Barre syndrome, Multiple myeloma, Peripheral autologous stem cell transplant

Kaynakça

• 1. Kyle R, Rajkumar SV: Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009, 23(1):3-9.
• 2. Morgan G, Davies F: Evolving treatment strategies for myeloma. British journal of cancer 2005, 92(2):217-221.
• 3. Al Hamed R, Bazarbachi AH, Malard F, Harousseau J-L, Mohty M: Current status of autologous stem cell transplantation for multiple myeloma. Blood cancer journal 2019, 9(4):1-10.
• 4. Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M, Palmer J, Pasquini M, Rizzo DJ, Saber W: Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone marrow transplantation 2015, 50(7):947-953.
• 5. Ruzhansky KM, Brannagan III TH: Neuromuscular complications of hematopoietic stem cell transplantation. Muscle & nerve 2015, 52(4):480-487.
• 6. Castro LH, Ropper AH: Human immune globulin infusion in Guillain‐Barré syndrome: Worsening during and after treatment. Neurology 1993, 43(5):1034-1034.
• 7. Durrheim DN: Guillain–Barré Syndrome. Hospital (Burkina Faso) 2004, 160:559-562.
• 8. Fujisaki G, Kami M, Murashige N, Kishi Y, Hori A, Chizuka A, Ugawa Y, Kobayashi K, Tanosaki R: Guillain–Barré syndrome associated with rapid immune reconstitution following allogeneic hematopoietic stem cell transplantation. Bone marrow transplantation 2006, 37(6):617-619.
• 9. Khouri J, Majhail NS: Advances in delivery of ambulatory autologous stem cell transplantation for multiple myeloma. Current opinion in supportive and palliative care 2017, 11(4):361-365.
• 10. Xu Y-L, Zhao W-H, Tang Z-Y, Li Z-Q, Long Y, Cheng P, Luo J: Guillain-Barre syndrome in a patient with multiple myeloma after bortezomib therapy: A case report. World Journal of Clinical Cases 2019, 7(18):2905.
• 11. Hadden R, Karch H, Hartung H-P, Zielasek J, Weissbrich B, Schubert J, Weishaupt A, Cornblath D, Swan A, Hughes R: Preceding infections, immune factors, and outcome in Guillain–Barré syndrome. Neurology 2001, 56(6):758-765.
• 12. Jacobs B, Rothbarth P, Van der Meché F, Herbrink P, Schmitz P, De Klerk M, Van Doorn P: The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998, 51(4):1110-1115.
• 13. Orlikowski D, Porcher R, Sivadon-Tardy V, Quincampoix J-C, Raphaël J-C, Durand M-C, Sharshar T, Roussi J, Caudie C, Annane D: Guillain–Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. Clinical infectious diseases 2011, 52(7):837-844.
• 14. Kang J-H, Sheu J-J, Lin H-C: Increased risk of Guillain-Barré Syndrome following recent herpes zoster: a population-based study across Taiwan. Clinical infectious diseases 2010, 51(5):525-530.
• 15. Zhang L, Arrington S, Keung Y-K: Guillain-Barré syndrome after transplantation. Leukemia & lymphoma 2008, 49(2):291-297.
• 16. Patchell RA: Neurological complications of organ transplantation. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 1994, 36(5):688-703.
• 17. Patchell RA, White CL, Clark AW, Beschorner WE, Santos GW: Neurologic complications of bone marrow transplantation. Neurology 1985, 35(3):300-300.
• 18. Poropatich KO, Walker CLF, Black RE: Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review. Journal of health, population, and nutrition 2010, 28(6):545.
• 19. Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K: Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. Journal of the National Comprehensive Cancer Network 2010, 8(Suppl_1):S-4-S-12.
• 20. Openshaw H, Slatkin N: CLINICAL SPECTRUM CT DEMYELINATING POLYNEUROPATHY AFTER BONE-MARROW TRANSPLANTATION (BMT). In: Neurology: 1994: LITTLE BROWN CO 34 BEACON STREET, BOSTON, MA 02108-1493; 1994: A277-A277.
• 21. Wen P, Alyea E, Simon D, Herbst R, Soiffer R, Antin J: Guillain-Barre syndrome following allogeneic bone marrow transplantation. Neurology 1997, 49(6):1711-1714